Page 121 - Genentech News Today

/PRNewswire/ -- Roots Analysis has announced the addition of "Antibody Drug Conjugate Market (7th Edition), 2023-2035" report to its list of offerings. The...

LiveNews Provides news reports of information as it happens in real time of politics, business, the economy and also reports on global issues and events from a New Zealand viewpoint.

Experts discuss the results of Protocol T study comparing anti-vascular endothelial growth factor (Anti-VEGF) agents for the treatment of diabetic macular edema (DME).

BioPharma

Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance...

The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.

The Human Cell Atlas’ overarching goal is to create a fine-grained picture of a healthy individual, along with an understanding of how that picture differs and changes throughout life

123 jump

Shares of Recursion Pharmaceuticals and GE Healthcare are both up sharply so far this year.

European markets were lower Wednesday as investors continue to digest earnings and the U.S. rating downgrade.